Prothena Plc Stock Today
| PRTA Stock | USD 16.01 4.06 33.97% |
Performance0 of 100
| Odds Of DistressLess than 6
|
Prothena Plc is trading at 16.01 as of the 20th of December 2024, a 33.97 percent increase since the beginning of the trading day. The stock's open price was 11.95. Prothena Plc has only a 6 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of November 2024 and ending today, the 20th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of December 2012 | Category Healthcare | Classification Health Care |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company was founded in 2012 and is based in Dublin, Ireland. Prothena Corp operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 53.81 M outstanding shares of which 8.06 M shares are at this time shorted by private and institutional investors with about 17.35 trading days to cover. More on Prothena plc
Moving together with Prothena Stock
Moving against Prothena Stock
Prothena Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsProthena Plc can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Prothena Plc's financial leverage. It provides some insight into what part of Prothena Plc's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prothena plc (PRTA) is traded on NASDAQ Exchange in USA. It is located in 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60 and employs 173 people. Prothena Plc is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 861.48 M. Prothena plc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 53.81 M outstanding shares of which 8.06 M shares are at this time shorted by private and institutional investors with about 17.35 trading days to cover.
Prothena plc currently holds about 508.8 M in cash with (133.91 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.84.
Check Prothena Plc Probability Of Bankruptcy
Ownership AllocationProthena Plc owns a total of 53.81 Million outstanding shares. The majority of Prothena plc outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Prothena plc to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Prothena Plc. Please pay attention to any change in the institutional holdings of Prothena plc as this could imply that something significant has changed or is about to change at the company. Also note that almost five million six hundred six thousand eight hundred sixty-seven invesors are currently shorting Prothena Plc expressing very little confidence in its future performance.
Check Prothena Ownership Details
Prothena Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 719.3 K | |
| Boxer Capital Llc | 2024-09-30 | 690 K | |
| Rock Springs Capital Management Lp | 2024-09-30 | 625 K | |
| Ubs Asset Mgmt Americas Inc | 2024-09-30 | 526.7 K | |
| Prosight Management, Lp | 2024-09-30 | 483.5 K | |
| Finepoint Capital Lp | 2024-09-30 | 433.5 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 415.3 K | |
| Federated Hermes Inc | 2024-09-30 | 404.9 K | |
| Northern Trust Corp | 2024-09-30 | 372.7 K | |
| Ecor1 Capital, Llc | 2024-09-30 | 11.6 M | |
| Fmr Inc | 2024-09-30 | 8.1 M |
Prothena Plc Historical Income Statement
Prothena Stock Against Markets
Prothena Plc Corporate Management
| Hideki MD | Chief Officer | Profile | |
| CPA CPA | Chief Controller | Profile | |
| Jennifer Zibuda | Director Communication | Profile | |
| Brandon Smith | Chief Officer | Profile | |
| Wagner Zago | Chief Scientific Officer | Profile | |
| Carol Karp | Chief Regulatory Officer | Profile | |
| David Ford | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Prothena plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Prothena Stock refer to our How to Trade Prothena Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Prothena Plc. If investors know Prothena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Prothena Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.46) | Revenue Per Share 2.482 | Quarterly Revenue Growth (0.99) | Return On Assets (0.16) | Return On Equity (0.23) |
The market value of Prothena plc is measured differently than its book value, which is the value of Prothena that is recorded on the company's balance sheet. Investors also form their own opinion of Prothena Plc's value that differs from its market value or its book value, called intrinsic value, which is Prothena Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Prothena Plc's market value can be influenced by many factors that don't directly affect Prothena Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Prothena Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Prothena Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Prothena Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.